A novel model-assisted design in phase I clinical trials: Bayesian optimal interval design

doi:10.12092/j.issn.1009-2501.2020.06.006

Abstract

Abstract: AIM: To introduce a novel and flexible model-assisted design for Phase I clinical trials: Bayesian optimal interval (BOIN) design, including the process of implementation, practical implementation, and evaluation of its performance. METHODS: BOIN design decides dose escalation/de-escalation by comparing the observed toxicity rate at the current dose with an escalation boundary and a de-escalation boundary that are optimized to minimize the probability of making incorrect decision of dose assignment. The application of the BOIN design is illustrated using a trial example. RESULTS: BOIN combines the advantages of the algorithm-based methods and model-based methods. It enjoys desirable statistical properties -it is optimal, safe, robust and easy to implement. Simulation study shows that the BOIN substantially outperforms the existing designs with higher accuracy to identify the maximum tolerated dose (MTD). CONCLUSION: BOIN design possesses the similar statistical performance to the much more complicated model-based designs. It is simple to implement, and easy to calibrate to meet the safety requirement mandated by regulatory agents. The BOIN design has been widely used in different types of cancers. It is a novel design that holds great potential to substantially improve phase I trials in China.

Key words: Phase I clinical trials, BION, "3+3" design, maximum tolerated dose

CLC Number:

R311

ZHONG Zihang, CHEN Feng, YUAN Ying, CHENG Jiancheng, YU Xuanxuan, YANG Min, TAN Mingmin, ZHAO Yang, BAI Jianling, YU Hao. A novel model-assisted design in phase I clinical trials: Bayesian optimal interval design[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 640-648.

References 35

[1]	Bretz F, Dette H, Pinheiro JC. Practical considerations for optimal designs in clinical dose finding studies [J]. Stat Med, 2010, 29(7/8): 731-742.
[2]	Zhou H, Murray TA, Pan H, et al. Comparative review of novel model-assisted designs for phase I clinical trials [J]. Stat Med, 2018, 37(14): 2208-2222.
[3]	Iasonos A, O'Quigley J. Adaptive dose-finding studies: a review of model-guided phase I clinical trials [J]. J Clin Onco, 2014, 32(23): 2505-2511.
[4]	Liu S, Yuan Y. Bayesian optimal interval designs for phase I clinical trials [J]. J Roy Stat Soc C, 2015, 64(3): 507-523.
[5]	Zhou H, Yuan Y, Nie L. Accuracy, safety, and reliability of novel phase I trial designs [J]. Clin Cancer Res, 2018, 24(18): 4357-4364.
[6]	Leung DH, Wang Y. Isotonic designs for phase I trials [J]. Control Clin Trials, 2001, 22(2): 126-138.
[7]	Bernhardt MB, De Guzman MM, Grimes A, et al. Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders [J]. Pediatr Blood Cancer, 2018, 65(1): e26759.
[8]	Place AE, Goldsmith K, Bourquin JP, et al. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies [J]. Future Oncol, 2018, 14(21): 2115-2129.
[9]	Muscal J. A phase I study of SGT-53, a TfRscFv-liposome-p53 complex, in children with refractory or recurrent solid tumors [EB/OL]. [2015-02-03]. https://clinicaltrials.gov/ct2/show/NCT02354547.
[10]	Phan J. Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer [EB/OL]. [2017-04-14]. https://clinicaltrials.gov/ct2/show/NCT03114462.
[11]	Wu J. TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma [EB/OL]. [2016-10-24]. https://clinicaltrials.gov/ct2/show/NCT02942264.
[12]	Loskog A. Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer [EB/OL]. [2016-03-10].https://clinicaltrials.gov/ct2/show/NCT02705196.
[13]	Lim B. A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer [EB/OL]. [2017-06-28]. https://clinicaltrials.gov/ct2/show/NCT03202316.
[14]	Li JE. The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors(HLX07Ib/II) [EB/OL]. [2018-07-05]. https://clinicaltrials.gov/ct2/show/NCT03577704.
[15]	Jazaeri AA, Yee C. T Cell Immunotherapy for Advanced Ovarian Cancer [EB/OL]. [2017-10-24]. https://clinicaltrials.gov/ct2/show/NCT03318900.
[16]	Badgwell BD. Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology [EB/OL]. [2017-11-06]. https://www.clinicaltrials.gov/ct2/show/NCT03330028.
[17]	Astellas Pharma Global Development I. A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors [EB/OL]. [2018-11-30]. https://clinicaltrials.gov/ct2/show/NCT03760081.
[18]	Al-Atrash G. Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia [EB/OL]. [2018-07-26]. https://clinicaltrials.gov/ct2/show/NCT03600155.
[19]	Sikora A. Binary Oncolytic Adenovirus in Combination With HER2-Specific CAR VST, Advanced HER2 Positive Solid Tumors (VISTA) [EB/OL]. [2018-11-14]. https://clinicaltrials.gov/ct2/show/NCT03740256.
[20]	Rezvani A, Andermann T. Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant [EB/OL]. [2016-06-17]. https://clinicaltrials.gov/ct2/show/NCT02805075.
[21]	Leonard JP, Abramson JS, Rutherford S. Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R) [EB/OL]. [2017-01-30]. https://clinicaltrials.gov/ct2/show/NCT03036904.
[22]	Hong DS. Study of Ixazomib and Erlotinib in Solid Tumors [EB/OL]. [2016-10-21]. https://clinicaltrials.gov/ct2/show/NCT02942095.
[23]	Fu S. SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors[EB/OL]. [2018-12-24]. https://clinicaltrials.gov/ct2/show/NCT03784677.
[24]	Yuan Y, Hess KR, Hilsenbeck SG, et al. Bayesian optimal Interval design: A simple and well-performing design for phase I oncology Trials [J]. Clin Cancer Res, 2016, 22(17): 4291-4301.
[25]	Cheung YK. Coherence principles in dose-finding studies [J]. Biometrika, 2005, 92(4): 863-873.
[26]	Lin Y, Shih WJ. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials [J]. Biostatistics, 2001, 2(2): 203-215.
[27]	O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer [J]. Biometrics, 1990, 46(1): 33-48.
[28]	Ji Y, Liu P, Li Y, et al. A modified toxicity probability interval method for dose-finding trials [J]. Clin Trials, 2010, 7(6): 653-663.
[29]	Guo W, Wang SJ, Yang S, et al. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2 [J]. Contemp Clin Trials, 2017, 58: 23-33.
[30]	Yan F, Mandrekar SJ, Yuan Y. Keyboard: A novel Bayesian toxicity probability interval design for phase I clinical trials[J]. Clin Cancer Res, 2017, 23(15): 3994-4003.
[31]	Lin R, Yin G. Bayesian optimal interval design for dose finding in drug-combination trials [J]. Stat Methods Med Res, 2017, 26(5): 2155-2167.
[32]	Yuan Y, Lin R, Li D, et al. Time-to-event Bayesian optimal Interval design to accelerate phase I trials [J]. Clin Cancer Res, 2018,24 (20): 4921-4930.
[33]	Mu R, Ying Y, Jin X, et al. gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points [J]. Biostatistics, 2018, 68(2): 289-308.
[34]	Lin R, Yin G. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials [J]. Stat Med, 2017, 36(26): 4106-4120.
[35]	Takeda K, Taguri M, Morita S. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes [J]. Pharm Stat, 2018, 17(4): 383-395.